Keyphrases
β-Thalassemia (β-thal)
100%
Transfusion-dependent Thalassemia
88%
Non-Hodgkin Lymphoma
76%
Thalassemia
73%
Israel
66%
Splenectomy
55%
Deferasirox
40%
Spleen
38%
Nonmalignant
33%
Poor Outcome
33%
Ga-67
33%
Gelatinous Bone Marrow Transformation
33%
Luspatercept
33%
Basic Fibroblast Growth Factor (bFGF)
33%
Silent Cerebral Infarction
33%
Antiphospholipid Antibodies
33%
Congenital Anemia
33%
Metagenomic Next-generation Sequencing (mNGS)
33%
Malignant Hematological Diseases
33%
Creatinine Clearance
33%
Hodgkin
33%
Human Epidermal Growth Factor Receptor 2 (HER2)
33%
Proximal Renal Tubular Dysfunction
33%
Adverse Effects
33%
Steal Phenomenon
33%
High Incidence
33%
Sarcoidosis
33%
Immunohistochemical Study
33%
Adult Patients
33%
Phase II Trial
33%
Prognostic Factors
33%
Aggressive non-Hodgkin Lymphoma
33%
Drug Effects
33%
VEGFR-3
33%
Diffuse Large B-cell Lymphoma (DLBCL)
33%
VEGF-D
33%
Vascular Endothelial Growth factor-C (VEGF-C)
33%
Alloimmunization
33%
Marrow
33%
Imatinib Mesylate
33%
Chronic Myeloid Leukemia
33%
Autoimmunization
33%
Clinical Characteristics
33%
Congenital Neutropenia
33%
Background Characteristics
33%
Genetic Background
33%
Alloantibody
27%
ELANE
26%
G6PC3
26%
Genetic Diagnosis
25%
Medicine and Dentistry
Non-Hodgkin Lymphoma
100%
Thalassemia
83%
Thalassemia Major
66%
Disease
56%
Receptor
40%
Adverse Event
40%
Deferasirox
38%
Splenectomy
38%
Next Generation Sequencing
38%
Vasculotropin D
33%
Beta Thalassemia
33%
Vasculotropin C
33%
Drug Effect
33%
Diffuse Large B-Cell Lymphoma
33%
Vasculotropin Receptor 3
33%
Kidney Tubule Disorder
33%
Luspatercept
33%
Fibroblast Growth Factor 2
33%
Creatinine Clearance
33%
Sarcoidosis
33%
Brain Infarction
33%
Imatinib
33%
Antiphospholipid Antibody
33%
Hodgkin's Lymphoma
33%
Blood Disorder
33%
Chronic Myelogenous Leukemia
33%
Anemia
33%
Artery Steal Syndrome
33%
Neutropenia
33%
Genetic Background
33%
Creatinine
27%
Placebo
23%
Plasma Cell
22%
Epidermal Growth Factor Receptor 2
22%
Malignant Neoplasm
22%
Infection
21%
Hematologic Malignancy
19%
Myeloid Transformation
19%
Beta2 Glycoprotein 1
16%
Cardiolipin Antibody
16%
Central Venous Catheter
16%
Nephropathy
16%
Magnetic Resonance Imaging
16%
Lymphoma
15%
Splenomegaly
14%
Fibroblast Growth Factor Receptor 1
14%
Lymphoma Cell
13%
Microvessel
12%
International Prognostic Index
12%
Patient with Non-Hodgkins Lymphoma
11%
